Search Results - "Luten, Marleen"

Vesicles generated during storage of red cells are rich in the lipid raft marker stomatin by Salzer, Ulrich, Zhu, Rong, Luten, Marleen, Isobe, Hirotaka, Pastushenko, Vassili, Perkmann, Thomas, Hinterdorfer, Peter, Bosman, Giel J.C.G.M.

“…BACKGROUND: The release of vesicles by red blood cells (RBCs) occurs in vivo and in vitro under various conditions. Vesiculation also takes place during RBC…”
Get full text

The proteome of red cell membranes and vesicles during storage in blood bank conditions by Bosman, Giel J.C.G.M., Lasonder, Edwin, Luten, Marleen, Roerdinkholder-Stoelwinder, Bregt, Novotný, Věra M.J., Bos, Harry, De Grip, Willem J.

“…BACKGROUND: During storage of red cells (RBCs) for transfusion, RBCs undergo a number of biochemical and morphologic changes. To be able to identify the…”
Get full text

Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods by Luten, Marleen, Roerdinkholder-Stoelwinder, Bregt, Schaap, Nicolaas P.M., De Grip, Willem J., Bos, Harry J., Bosman, Giel J.C.G.M.

“…BACKGROUND: The use of fresh red blood cells (RBCs) is recommended for critically ill patients and patients undergoing surgery, although there is no conclusive…”
Get full text

The proteome of red cell membranes and vesicles during storage in blood bank conditions by BOSMAN, Giel J. C. G. M, LASONDER, Edwin, LUTEN, Marleen, ROERDINKHOLDER-STOELWINDER, Bregt, NOVOTNY, Vera M. J, BOS, Harry, DE GRIP, Willem J

“…During storage of red cells (RBCs) for transfusion, RBCs undergo a number of biochemical and morphologic changes. To be able to identify the mechanisms…”
Get full text

Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction by Kerkhoffs, Jean‐Louis H., Van Putten, Wim L. J., Novotny, Viera M. J., Te Boekhorst, Peter A.W., Schipperus, Martin R., Zwaginga, Jaap Jan, Van Pampus, Lizzy C. M., De Greef, Georgine E., Luten, Marleen, Huijgens, Peter C., Brand, Anneke, Van Rhenen, Dick J.

“…Summary Pathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic…”
Get full text

Rituximab-Pecc Induction Followed By 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study by Lugtenburg, Pieternella J, Zijlstra, Josée M, Doorduijn, Jeanette K, Böhmer, Lara H, van Marwijk Kooy, Marinus, Hoogendoorn, Mels, Berenschot, Henriette W, Beeker, Aart, Valster, Fransje, Schouten, Harry C., Luten, Marleen, Hofwegen, Henk, Chitu, Dana A, Brouwer, Rolf E, van Imhoff, Gustaaf W

“…Background: Patients with relapsed/ refractory diffuse large B-cell lymphoma (DLBCL) after- or not eligible for autologous stem cell transplantation (ASCT)…”
Get full text

Rituximab-PECC Induction Followed by 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study by Lugtenburg, Pieternella J, Zijlstra, Josée M, Doorduijn, Jeanette K, Böhmer, Lara H, van Marwijk Kooy, Marinus, Hoogendoorn, Mels, Berenschot, Henriette W, Beeker, Aart, Valster, Fransje A, Schouten, Harry C, Luten, Marleen, Chitu, Dana A, Brouwer, Rolf E, van Imhoff, Gustaaf W

“…Abstract 2729 Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after- or not eligible for autologous stem cell transplantation (ASCT)…”
Get full text

Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction by Kerkhoffs, Jean-Louis Henry, van Putten, Wim L.J., Novotny, Viera M.J., Te Boekhorst, Peter A. W., Schipperus, Martin R., Zwaginga, Jaap Jan, van Pampus, Lizzy C.M., de Greef, Georgine E, Luten, Marleen, Huijgens, Peter C, Brand, Anneke, van Rhenen, Dick J.

“…Pathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic…”
Get full text

Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients by Zwaginga, Jaap Jan, van der Holt, Ronnie, Biemond, Bart J., Boekhorst, Peter A.W. te, Levin, Mark, Vreughdenhil, Art, Huijgens, P.C., Brand, Anneke, van der Griend, Rene, Luten, Marleen, Pruijt, Hans, Weerdt, Okke de, van Pampus, Elisabeth, Zweegman, Sonja, Hollestein, Rene, Koene, Harry R.

“…Abstract 2514 The overall short term effectivity of Rituximab in the treatment of ITP is reported to be around 50%. In most studies the traditional CD20 dosing…”
Get full text

A single assay for multiple storage-sensitive red blood cell characteristics by means of infrared spectroscopy by Pistorius, Arthur M.A., Luten, Marleen, Bosman, Giel J.C.G.M., DeGrip, Willem J.

“…BACKGROUND: To maintain a high quality of red blood cells (RBCs), RBC characteristics must be followed during storage under blood bank conditions. By means of…”
Get full text

Red cell concentrates of hemochromatosis patients comply with the storage guidelines for transfusion purposes by Luten, Marleen, Roerdinkholder-Stoelwinder, Bregt, Rombout-Sestrienkova, Eva, De Grip, Willem J., Bos, Harry J., Bosman, Giel J.C.G.M.

“…BACKGROUND: Therapeutic phlebotomy is the preferred treatment for iron overload associated with hemochromatosis. In the Netherlands, red blood cell…”
Get full text